CRISPR Therapeutics AG (CRSP) Shares Outstanding (2015 - 2026)

CRISPR Therapeutics AG has disclosed Shares Outstanding (Entity) across 12 years of filings, most recently posting $96.7 million for Q2 2026.

• In Q2 2026, Shares Outstanding (Entity) rose 9.37% year-over-year to $96.7 million; the TTM figure through Jun 2026 stood at $96.7 million (up 9.37% YoY), while the FY2025 annual figure was $95.9 million, up 11.84% from the prior year.
• Shares Outstanding (Entity) came in at $96.7 million for Q2 2026 at CRISPR Therapeutics AG, roughly flat from $96.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $96.7 million in Q2 2026 to a low of $77.4 million in Q1 2022.
• Average Shares Outstanding (Entity) over 5 years is $84.9 million, with a median of $84.9 million recorded in 2024.
• Year-over-year, Shares Outstanding (Entity) rose 1.51% in 2023 and grew 11.84% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $78.5 million in 2022, then grew by 1.95% to $80.0 million in 2023, then advanced by 7.12% to $85.7 million in 2024, then gained by 11.84% to $95.9 million in 2025, then increased by 0.8% to $96.7 million in 2026.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $96.7 million in Q2 2026, $96.4 million in Q1 2026, and $95.9 million in Q4 2025.